Monthly research recap
PTSD research: October 2026
What October 2026's 6 new studies found, synthesized from the papers below. All PTSD research →
The synthesis
Synthesized from 6 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for PTSD, post-traumatic stress disorder, traumatic stress, then ranked by relevance.
Research indexed in October 2026 on PTSD was dominated by small, early-stage studies of adjunctive or experimental treatments rather than definitive efficacy trials. Ketamine showed short-term symptom reductions across most reviewed studies, but the largest effect came from a small uncontrolled veteran study and the authors call the evidence preliminary; mindfulness and mind-body therapies showed improvements in symptoms, sleep, and interoceptive awareness, while adding targeted memory reactivation to imagery rehearsal therapy gave no extra benefit. The main caveats are small samples, mostly short follow-up, and a lack of large placebo-controlled confirmation, with a 210-patient sham-controlled ketamine trial still only at protocol stage.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Impact of Mindfulness Training on PTSD Symptoms and Sleep Quality in a Cohort of Firefighters 2026 | quasi-experimental study | 70 | Supports | An eight-session mindfulness program was associated with significantly lower PTSD symptom scores and better sleep quality than no intervention at post-test and two-month follow-up. |
| Ketamine administration reduced conditioned defensive behaviour and upregulated protein expression associated with neuroplasticity in a planarian model of aversive memory reactivation. 2026 | preclinical experimental study | 15 | Supports | In planaria undergoing aversive memory reactivation, 10 μM ketamine reduced defensive behaviors versus vehicle and was accompanied by enrichment of neuroplasticity-related protein pathways. |
| Clinical and neurophysiological effects of imagery rehearsal therapy and targeted memory reactivation in post-traumatic stress disorder 2026 | RCT | 36 | Mixed | Imagery Rehearsal Therapy significantly improved PTSD symptoms, insomnia, nightmares, and depressive symptoms, but adding Targeted Memory Reactivation produced no additional benefit on these outcomes. |
| Efficacy and safety of ketamine for post‐traumatic stress disorder: A systematic review with narrative synthesis and consideration of military and veteran populations 2026 | systematic review | 383 | Supports | Most of eight included studies reported short-term PTSD symptom reductions after ketamine or esketamine, with the largest effect from a small uncontrolled veteran study, and the authors conclude the evidence remains preliminary. |
| Multi-center, randomized controlled efficacy and comparative-effectiveness study evaluating ketamine, stellate ganglion blocks, combination treatment, and sham treatments for posttraumatic stress disorder and traumatic brain injury-associated headache: a study protocol 2026 | RCT protocol | 210 | Unclear | Describes a planned double-blind, sham-controlled multicenter trial comparing ketamine, stellate ganglion blocks, and combination treatment on headache impact and PTSD symptoms at 4 weeks; no outcome data are reported. |
| Enhancing interoceptive awareness in veterans with PTSD through Mind-Body Therapy in Denmark: A mixed-methods study 2026 | mixed-methods study within an RCT | 42 | Supports | Mind-body therapy plus treatment-as-usual significantly improved all eight interoceptive awareness domains versus treatment-as-usual alone, with some effects sustained at 12 months, and interviews described sensing the body, allowing pain, and restoring agency. |
Points of agreement
- Several interventions (mindfulness, imagery rehearsal therapy, mind-body therapy, ketamine) were associated with reductions in PTSD symptoms or related outcomes.
- Benefits were generally measured over short windows, from post-intervention to a few months.
- Authors across studies describe the evidence base as preliminary or in need of stronger controlled confirmation.
Conflicts
- Adding targeted memory reactivation to imagery rehearsal therapy added no symptom benefit, despite prior findings in idiopathic nightmares.
- Ketamine trial results are described as conflicting, motivating a new comparative-effectiveness trial.
Gaps
- Few large placebo- or sham-controlled trials with PTSD symptom outcomes have reported results.
- Long-term durability beyond 2-12 months is largely unestablished.
- Blinding and control conditions vary, and several studies are uncontrolled or quasi-experimental.
- Populations studied are narrow (firefighters, veterans, small clinical samples), limiting generalizability.
- Dose-response and safety data for repeated ketamine are limited.
- Preclinical work in invertebrates cannot establish clinical efficacy.